NCT05411484View on ClinicalTrials.gov

Investigation of Laser Assisted Drug Delivery of NanoDOX®

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 29, 2023

Primary Completion Date

October 2, 2024

Study Completion Date

February 28, 2025

Conditions
Wounds and Injury
Interventions
DRUG

NanoDOX® Hydrogel

NanoDOX® Hydrogel (Doxycycline Monohydrate USP) will be applied on the areas of the skin previously treated by the Co2 Ablative Fractional Laser and also on a small non treated area of the subject's skin

DEVICE

CO2 Ablative Fractional Laser

CO2 Ablative Fractional Laser will be applied to healthy skin areas

Trial Locations (1)

02114

MGH Clinical Unit for Research Trials And Outcome, Boston

All Listed Sponsors
collaborator

NanoSHIFT LLC

INDUSTRY

lead

Massachusetts General Hospital

OTHER

NCT05411484 - Investigation of Laser Assisted Drug Delivery of NanoDOX® | Biotech Hunter | Biotech Hunter